<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182052</url>
  </required_header>
  <id_info>
    <org_study_id>00-100</org_study_id>
    <nct_id>NCT00182052</nct_id>
    <nct_alias>NCT00139412</nct_alias>
  </id_info>
  <brief_title>Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer</brief_title>
  <official_title>Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer: A Randomized Double-Blind, Placebo Controlled Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study it to learn the effects (good or bad) that rosiglitazone has on&#xD;
      patients and their prostate cancer. This study is going to look at what effects rosiglitazone&#xD;
      has on prostate specific antigen (PSA) levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Patients will be randomly assigned to initial treatment with either rosiglitazone or&#xD;
           placebo orally twice daily, every day as long as there is no disease progression or&#xD;
           serious side effects. Patients will be asked to complete a drug log to keep track of the&#xD;
           medication.&#xD;
&#xD;
        -  Before treatment begins the following tests will be performed: physical exam; bone scan;&#xD;
           blood work (including PSA level test) and a urine sample.&#xD;
&#xD;
        -  While on this study the following tests and procedures will be done once a month: review&#xD;
           of side effects and routine blood tests (including PSA levels).&#xD;
&#xD;
        -  While on this study the following tests and procedures will be done on months 2 and 4:&#xD;
           review of side effects; routine blood tests (including PSA levels) and urine tests.&#xD;
&#xD;
        -  If the patient's disease progressed the treatment code will be broken and if the patient&#xD;
           was on placebo, they will have the option to begin taking rosiglitazone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the activity of rosiglitazone by comparing changes in PSA doubling time between rosiglitazone-treated and placebo-treated men.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate time to PSA progression as a measure of the activity of rosiglitazone.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Avandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given orally twice daily.</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Biochemical disease progression following local therapy defined as three rises in PSA&#xD;
             with each PSA determination at least 4 weeks apart and each PSA value &gt; or = 0.2ng/ml&#xD;
&#xD;
          -  For men treated with radical prostatectomy, PSA &gt; or = 2 ng/ml&#xD;
&#xD;
          -  For men treated with primary radiation therapy or post-prostatectomy radiation&#xD;
             therapy, PSA &gt; or = 2 ng/ml and &gt; 150% post-radiation nadir&#xD;
&#xD;
          -  Not an appropriate candidate for salvage radiation therapy or salvage prostatectomy&#xD;
&#xD;
          -  Baseline PSADT &lt; 24 months&#xD;
&#xD;
          -  CALGB performance status of 0,1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Prior hormonal therapy for recurrent prostate cancer&#xD;
&#xD;
          -  Prior chemotherapy for prostate cancer&#xD;
&#xD;
          -  Current treatment with insulin or an oral hypoglycemic&#xD;
&#xD;
          -  History of treatment with thiazolidinediones&#xD;
&#xD;
          -  Radiation therapy within 6 months&#xD;
&#xD;
          -  SGOT &gt; 1.5 x ULN&#xD;
&#xD;
          -  Fasting blood glucose &lt; 60 mg/dl&#xD;
&#xD;
          -  NYHA Class 3 or 4 cardiac status&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 1;101(7):1569-74.</citation>
    <PMID>15468186</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>May 22, 2013</last_update_submitted>
  <last_update_submitted_qc>May 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Matthew R. Smith, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>rosiglitazone</keyword>
  <keyword>Avandia</keyword>
  <keyword>androgen dependant prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

